Search for "H-bonding" in Full Text gives 123 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2013, 9, 2537–2543, doi:10.3762/bjoc.9.288
Graphical Abstract
Scheme 1: Intermolecular O-addition to alkynes: challenge and opportunity.
Scheme 2: Acid as the critical additive for optimal performance.
Scheme 3: Reactions of internal alkyne and other O-nucleophiles. Isolated yields are given in paranthesis. aA...
Beilstein J. Org. Chem. 2013, 9, 2265–2319, doi:10.3762/bjoc.9.265
Graphical Abstract
Scheme 1: Scaled industrial processes for the synthesis of simple pyridines.
Scheme 2: Synthesis of nicotinic acid from 2-methyl-5-ethylpyridine (1.11).
Scheme 3: Synthesis of 3-picoline and nicotinic acid.
Scheme 4: Synthesis of 3-picoline from 2-methylglutarodinitrile 1.19.
Scheme 5: Picoline-based synthesis of clarinex (no yields reported).
Scheme 6: Mode of action of proton-pump inhibitors and structures of the API’s.
Scheme 7: Hantzsch-like route towards the pyridine rings in common proton pump inhibitors.
Figure 1: Structures of rosiglitazone (1.40) and pioglitazone (1.41).
Scheme 8: Synthesis of rosiglitazone.
Scheme 9: Syntheses of 2-pyridones.
Scheme 10: Synthesis and mechanism of 2-pyrone from malic acid.
Scheme 11: Polymer-assisted synthesis of rosiglitazone.
Scheme 12: Synthesis of pioglitazone.
Scheme 13: Meerwein arylation reaction towards pioglitazone.
Scheme 14: Route towards pioglitazone utilising tyrosine.
Scheme 15: Route towards pioglitazone via Darzens ester formation.
Scheme 16: Syntheses of the thiazolidinedione moiety.
Scheme 17: Synthesis of etoricoxib utilising Negishi and Stille cross-coupling reactions.
Scheme 18: Synthesis of etoricoxib via vinamidinium condensation.
Figure 2: Structures of nalidixic acid, levofloxacin and moxifloxacin.
Scheme 19: Synthesis of moxifloxacin.
Scheme 20: Synthesis of (S,S)-2,8-diazabicyclo[4.3.0]nonane 1.105.
Scheme 21: Synthesis of levofloxacin.
Scheme 22: Alternative approach to the levofloxacin core 1.125.
Figure 3: Structures of nifedipine, amlodipine and clevidipine.
Scheme 23: Mg3N2-mediated synthesis of nifedipine.
Scheme 24: Synthesis of rac-amlodipine as besylate salt.
Scheme 25: Aza Diels–Alder approach towards amlodipine.
Scheme 26: Routes towards clevidipine.
Figure 4: Examples of piperidine containing drugs.
Figure 5: Discovery of tiagabine based on early leads.
Scheme 27: Synthetic sequences to tiagabine.
Figure 6: Structures of solifenacin (2.57) and muscarine (2.58).
Scheme 28: Enantioselective synthesis of solifenacin.
Figure 7: Structures of DPP-4 inhibitors of the gliptin-type.
Scheme 29: Formation of inactive diketopiperazines from cis-rotameric precursors.
Figure 8: Co-crystal structure of carmegliptin bound in the human DPP-4 active site (PDB 3kwf).
Scheme 30: Improved route to carmegliptin.
Figure 9: Structures of lamivudine and zidovudine.
Scheme 31: Typical routes accessing uracil, thymine and cytosine.
Scheme 32: Coupling between pyrimidones and riboses via the Vorbrüggen nucleosidation.
Scheme 33: Synthesis of lamivudine.
Scheme 34: Synthesis of raltegravir.
Scheme 35: Mechanistic studies on the formation of 3.22.
Figure 10: Structures of selected pyrimidine containing drugs.
Scheme 36: General preparation of pyrimidines and dihydropyrimidones.
Scheme 37: Synthesis of imatinib.
Scheme 38: Flow synthesis of imatinib.
Scheme 39: Syntheses of erlotinib.
Scheme 40: Synthesis of erlotinib proceeding via Dimroth rearrangement.
Scheme 41: Synthesis of lapatinib.
Scheme 42: Synthesis of rosuvastatin.
Scheme 43: Alternative preparation of the key aldehyde towards rosuvastatin.
Figure 11: Structure comparison between nicotinic acetylcholine receptor agonists.
Scheme 44: Syntheses of varenicline and its key building block 4.5.
Scheme 45: Synthetic access to eszopiclone and brimonidine via quinoxaline intermediates.
Figure 12: Bortezomib bound in an active site of the yeast 20S proteasome ([114], pdb 2F16).
Scheme 46: Asymmetric synthesis of bortezomib.
Figure 13: Structures of some prominent piperazine containing drugs.
Figure 14: Structural comparison between the core of aplaviroc (4.35) and a type-1 β-turn (4.36).
Scheme 47: Examplary synthesis of an aplaviroc analogue via the Ugi-MCR.
Scheme 48: Syntheses of azelastine (5.1).
Figure 15: Structures of captopril, enalapril and cilazapril.
Scheme 49: Synthesis of cilazapril.
Figure 16: Structures of lamotrigine, ceftriaxone and azapropazone.
Scheme 50: Synthesis of lamotrigine.
Scheme 51: Alternative synthesis of lamotrigine (no yields reported).
Figure 17: Structural comparison between imiquimod and the related adenosine nucleoside.
Scheme 52: Conventional synthesis of imiquimod (no yields reported).
Scheme 53: Synthesis of imiquimod.
Scheme 54: Synthesis of imiquimod via tetrazole formation (not all yields reported).
Figure 18: Structures of various anti HIV-medications.
Scheme 55: Synthesis of abacavir.
Figure 19: Structures of diazepam compared to modern replacements.
Scheme 56: Synthesis of ocinaplon.
Scheme 57: Access to zaleplon and indiplon.
Scheme 58: Different routes towards the required N-methylpyrazole 6.65 of sildenafil.
Scheme 59: Polymer-supported reagents in the synthesis of key aminopyrazole 6.72.
Scheme 60: Early synthetic route to sildenafil.
Scheme 61: Convergent preparations of sildenafil.
Figure 20: Comparison of the structures of sildenafil, tadalafil and vardenafil.
Scheme 62: Short route to imidazotriazinones.
Scheme 63: Alternative route towards vardenafils core imidazotriazinone (6.95).
Scheme 64: Bayer’s approach to the vardenafil core.
Scheme 65: Large scale synthesis of vardenafil.
Scheme 66: Mode of action of temozolomide (6.105) as methylating agent.
Scheme 67: Different routes to temozolomide.
Scheme 68: Safer route towards temozolomide.
Figure 21: Some unreported heterocyclic scaffolds in top market drugs.
Beilstein J. Org. Chem. 2013, 9, 342–391, doi:10.3762/bjoc.9.39
Graphical Abstract
Figure 1: Change of electron distribution between HS and LS states of an octahedral iron(II) coordination com...
Figure 2: Types of spin transition curves in terms of the molar fraction of HS molecules, γHS(T), as a functi...
Figure 3: Single crystal UV–vis spectra of the spin crossover compound [Fe(ptz)6](BF4)2 (ptz = 1-propyltetraz...
Figure 4: Thermal spin crossover in [Fe(ptz)6](BF4)2 (ptz = 1-propyltetrazole) recorded at three different te...
Figure 5: (a) Mössbauer spectra of the LS compound [Fe(phen)3]X2 recorded over the temperature range 300–5 K....
Figure 6: (left) Demonstration of light-induced spin state trapping (LIESST) in [Fe(ptz)6]BF4)2 with 57Fe Mös...
Figure 7: Schematic representation of the pressure influence (p2 > p1) on the LS and HS potential wells of an...
Figure 8: χMT versus T curves at different pressures for [Fe(phen)2(NCS)2], polymorph II. (Reproduced with pe...
Figure 9: Molecular structure (a) and γHS(T) curves at different pressures for [CrI2(depe)2] (b) (Reproduced ...
Figure 10: HS molar fraction γHS versusT at different pressures for [Fe(phy)2](BF4)2. The hysteresis loop broa...
Figure 11: Proposed structure of the polymeric [Fe(4R-1,2,4-triazole)3]2+ spin crossover cation (a) and plot o...
Figure 12: Temperature dependence of the HS fraction γHS(T), determined from Mössbauer spectra of [Fe(II)xZn1-x...
Figure 13: Influence of the noncoordinated anion on the spin transition curve γHS(T) near the transition tempe...
Figure 14: Spin transition curves γHS(T) for different solvates of the SCO complexes. [Fe(II)(2-pic)3]Cl2·Solv...
Figure 15: ST curves γHS(T) of the deuterated solvates of [Fe(II)(2-pic)3]Cl2·Solv with Solv = C2D5OH and C2H5...
Figure 16: Sketch of the two-step spin transition; [LS–LS] pair is diamagnetic, [LS–HS] is paramagnetic and th...
Figure 17: (left) Temperature dependence of χMT for {[Fe(L)(NCX)2]2bpym}(L = bpym or bt and X = S or Se). (rig...
Figure 18: Temperature dependence of χMT for [bpym, NCS−] (left) and [bpym, NCSe−] (right) at different pressu...
Figure 19: 57Fe Mössbauer spectra of [bpym, NCSe−] measured at 4.2 K at zero field (a) and at 5 T (b) (see tex...
Figure 20: Temperature dependence of χMT for [Fe2(L)3](ClO4)4·2H2O showing a complete two-step spin conversion...
Figure 21: (a) View of the dinuclear unit in the crystal structure of [Fe2(Hsaltrz)5(NCS)4]·4MeOH. (b) Tempera...
Figure 22: (left) AFM pattern recorded in tapping mode at room temperature on hexagonal single crystals of [Fe3...
Figure 23: (right) Stepwise SCO in an Fe4 [2 × 2] grid, which reveals a smooth magnetic profile under ambient ...
Figure 24: (left) View of the discrete nanoball made of Fe(II) SCO units as well as Cu(I) building blocks. (ri...
Figure 25:
(left) Linear dependency between T1/2 in the heating (Δ) and cooling () modes versus the anion volu...
Figure 26: (left) View of the linear chain structure of [Fe(1,2-bis(tetrazol-1-yl)propane)3]2+ along the a axi...
Figure 27: (left) View of the 2D layered structure of [Fe(btr)2(NCS)2]·H2O (at 293 K). The water molecules (in...
Figure 28: (left) Three interpenetrated square networks for [Fe(bpb)2(NCS)2]·MeOH. (right) χMT versus T plot s...
Figure 29: Part of the crystal structure of [Fe{N(entz)3}](BF4)2 (T = 293 K) [335,336]. (Reproduced with permission fro...
Figure 30: (left) Projection of the crystal structure of [Fe(btr)3](ClO4)2 along the c axis revealing a 3D str...
Figure 31: Size-dependent SCO properties in [Fe(pz)Pt(CN)4] (left), change of color upon spin state transition...
Figure 32: Schematic showing the epitaxial growth of polymer {Fe(pz)[Pt(CN)4]} and the spin transition propert...
Figure 33: Microcontact printing (μCP) of nanodots on Si-wafer of [Fe(ptz)6](BF4)2 after deposition of crystal...
Figure 34: (left) Projection of the two independent cations of [Fe(C6–trenH)]2+ with atom numbering scheme (15...
Figure 35: (a) χMT versus T for [Fe(C16-trenH)]Cl2·0.5H2O and variation of the distance d with temperature (T)...
Figure 36: Schematic illustration of the structure of compounds [Fe(Cn-tba)3]X2 adopting a columnar mesophase ...
Figure 37: Temperature dependence of the magnetic moment (M) at 1000 Oe and DSC profiles (inset; 5 °C/min) of ...
Figure 38: Porous structure of the SCO-PMOFs {Fe(pz)[M(II)(CN)4]} (left), representation of the host–guest int...
Figure 39: Porous structure of the guest-free SCO-PMOF’s {Fe(pz)[M(II)(CN)4]} (left), magnetic properties of t...
Figure 40: (left) The 3D porous structure of {Fe(pz)[Pt(CN)4]}·0.5(CS(NH2)2) (1) and {Fe(pz)[Pd(CN)4]}·1.5H2O·...
Figure 41: Top: The 3D porous structure of {Fe(dpe)[Pt(CN)4]}·phenazine in a direction close to [101] emphasiz...
Figure 42: View of the segregated stacking of [Ni(dmit)2]− and [Fe(sal2-trien)]+ in [Fe(qsal)2][Ni(dmit)2]3·CH3...
Figure 43: Thin films based on Fe(III) compounds coordinated to Terthienyl-substituted QsalH ligands [434] together...
Figure 44: Left: Temperature-dependent emission spectra for [Fe2(Hsaltrz)5(NCS)4]·4MeOH at λex = 350 nm over t...
Beilstein J. Org. Chem. 2013, 9, 26–35, doi:10.3762/bjoc.9.4
Graphical Abstract
Scheme 1: Molecular structures of the investigated four-ring bent-core compounds 1a–1f.
Scheme 2: Synthetic details of the compounds 1a–1f. Reagents and conditions: i. 5% Pd/C, H2, EtOAc stirring, ...
Figure 1: Microphotographs of compounds 1b and 1c in the nematic phase during the cooling cycle. (a) Birefrin...
Figure 2: DSC trace of 1c obtained during initial heating and cooling cycles scanned at a rate of 10 K/min.
Figure 3: Molecular structure of 1a optimized at the DFT level. The bent angle is 143°, and the three dihedra...
Beilstein J. Org. Chem. 2012, 8, 1814–1818, doi:10.3762/bjoc.8.207
Graphical Abstract
Figure 1: Structure of (1R,2R)-N,N’-bis[(4-iodocuban-1-yl)methylene]-trans-1,2-diamino cyclohexane (1).
Figure 2: M06L DFT global minima for (a) (1R,2R)-N,N’-bis[(4-iodocuban-1-yl)methylene]-trans-1,2-diaminocyclo...
Beilstein J. Org. Chem. 2012, 8, 1360–1365, doi:10.3762/bjoc.8.157
Graphical Abstract
Figure 1: Cinchona alkaloid-derived catalysts screened for condition optimization (Table 1).
Scheme 1: A one-pot synthesis of enantioenriched 3,3-diaryloxindoles.
Beilstein J. Org. Chem. 2012, 8, 1161–1171, doi:10.3762/bjoc.8.129
Graphical Abstract
Figure 1: List of primary structures and abbreviations for the peptides studied in this work. The [Leu11-OMe]...
Scheme 1: Synthesis of ψ[CS-NH]2. 1: Coupling in the presence of EDC/HOBt. 2: Deprotection by using TFA/DCM. ...
Scheme 2: Synthesis of ψ[CS-NH]5. 1: Coupling in the presence of EDC/HOBt. 2: Deprotection by using TFA/DCM. ...
Scheme 3: Synthesis of ψ[CS-NH]9. 1: Deprotection by catalytic hydrogenation with Pd/C. 2: Coupling with n-Oc...
Figure 2: RP-HPLC profiles obtained for [Leu11-OMe] trichogin GA IV (tric-OMe) and its ψ[CS-NH]2, ψ[CS-NH]5, ...
Figure 3: Far-UV (panel I) and near-UV (panel II) CD spectra of [Leu11-OMe] trichogin GA IV (tric-OMe) and it...
Figure 4: FT-IR absorption spectra (3550–3200 cm−1 region) in CDCl3 solution of [Leu11-OMe] trichogin GA IV (...
Figure 5: Region of the amide NH protons in the H/H-ROESY spectrum of ψ[CS-NH]9 (400 MHz, 1 mM in CD3CN solut...
Figure 6: Fingerprint region of the H/H-ROESY spectrum of ψ[CS-NH]9 (400 MHz, 1 mM in CD3CN solution, 298 K)....
Figure 7: Fingerprint region of the H/H-ROESY spectrum of ψ[CS-NH]9 (400 MHz, 1 mM in CD3CN solution, 298 K)....
Figure 8: Ribbon representation of the lowest energy (138.7 kcal/mol) 3D structure obtained for ψ[CS-NH]9. Al...
Beilstein J. Org. Chem. 2012, 8, 129–154, doi:10.3762/bjoc.8.15
Graphical Abstract
Scheme 1: Examples for bent mesogens containing salicylideneimine moieties.
Scheme 2: Synthetic pathway to prepare compounds OH 1.
Figure 1: Polarising optical microscopy images. a) Compound OH 1a: Grainy texture with smectic Schlieren area...
Figure 2: X-ray diffraction pattern of a powderlike sample of OH 1b at 131 °C (inset: Small angle region; low...
Figure 3: Electro-optical behaviour of compound OH 1a: a) current response curve (U = 182 Vpp, f = 30 Hz, T =...
Figure 4: Switching behaviour of compound H 1a, which depends on how quickly the electric field is switched o...
Scheme 3: Reaction pathways to prepare the monosalicylideneaniline compounds OH 2a–j.
Figure 5: Compound OH 2a: Texture of the SmCP phase at 126 °C.
Figure 6: a) 2D X-ray pattern of a surface-aligned sample of compound OH 2a at 128 °C (lower part of the patt...
Figure 7: Electro-optical switching behaviour of compound OH 2a: a) current response (U = 230 Vpp, f = 25 Hz, ...
Scheme 4: Synthetic steps followed to prepare the compounds OH 3 and OH 4.
Figure 8: Optical photomicrographs of compound OH 3a: a) On cooling of the isotropic liquid; c) U = 0 V; b) U...
Figure 9: Electro-optical behaviour of compound OH 3a: a) Current response curve (U = 308 Vpp, f = 35 Hz, T =...
Figure 10: Growth of a fan-shaped texture from lancetlike filaments upon cooling of the isotropic liquid of co...
Figure 11: a) 2D X-ray pattern of a surface-aligned sample of compound OH 3b at 160 °C (lower part of the patt...
Figure 12: Compound OH 3b: Texture of the SmCPA phase in dependence on the polarity of the applied D.C. field.
Figure 13: Compound OH 4b, exhibiting a fan-shaped texture together with a Schlieren texture upon cooling of t...
Figure 14: 2D X-ray diffraction pattern of a partially surface-aligned sample of OH 4b at 115 °C (inset: Small...
Figure 15: Switching behaviour of compound OH 4b at 120 °C: a) Current response curve (U = 116 Vpp, f = 40 Hz, ...
Figure 16: Compound OH 4d: a) Microphotograph of a growing fringe pattern of a SmCP phase upon cooling of the ...
Figure 17: Electro-optical behaviour observed on the fan-shaped texture of compound OH 4d; UD.C. = 47 V; T = 1...
Figure 18: a) 2D X-ray diffraction pattern for a surface-aligned sample of OH 4d at 122 °C on cooling; b) χ-sc...
Scheme 5: Reaction steps employed for the preparation of the compounds OH 5 and OH 6.
Figure 19: Compound OH 5d: Optical photomicrographs of chiral domains at 122 °C; polariser and analyser are un...
Figure 20: Compound OH 5b: a), b) Chiral domains at 175 °C, 0 V, polarisers uncrossed by about ±8° from the 90...
Figure 21: X-ray diffraction patterns of compounds OH 5: a) Pattern of a powderlike sample of compound OH 5g a...
Figure 22: Photomicrographs of compound OH 5f: a) Appearance of spiral filaments on slow cooling of the isotro...
Figure 23: Current response of compound OH 6b exhibiting two repolarisation peaks proving an antiferroelectric...
Figure 24: On cooling the isotropic liquid phase of compound OH 6c; a Schlieren texture together with fringe p...
Figure 25: Electro-optical behaviour of compound OH 6c: a) Current response (UA.C. = 17 V/µm, f = 39 Hz, T = 1...
Beilstein J. Org. Chem. 2011, 7, 442–495, doi:10.3762/bjoc.7.57
Graphical Abstract
Figure 1: Structures of atorvastatin and other commercial statins.
Figure 2: Structure of compactin.
Scheme 1: Synthesis of pentasubstituted pyrroles.
Scheme 2: [3 + 2] Cycloaddition to prepare 5-isopropylpyrroles.
Scheme 3: Regiospecific [3 + 2] cycloaddition to prepare the pyrrole scaffold.
Scheme 4: Formation of the pyrrole core of atorvastatin via [3 + 2] cycloaddition.
Scheme 5: Formation of pyrrole 33 via the Paal–Knorr reaction.
Scheme 6: Convergent synthesis towards atorvastatin.
Figure 3: Binding pocket of sunitinib in the TRK KIT.
Scheme 7: Synthesis of sunitinib.
Scheme 8: Alternative synthesis of sunitinib.
Scheme 9: Key steps in the syntheses of sumatriptan and zolmitriptan.
Scheme 10: Introduction of the N,N-dimethylaminoethyl side chain.
Scheme 11: Japp–Klingemann reaction in the synthesis of sumatriptan.
Scheme 12: Synthesis of the intermediate sulfonyl chlorides 62 and 63.
Scheme 13: Alternative introduction of the sulfonamide.
Scheme 14: Negishi-type coupling to benzylic sulfonamides.
Scheme 15: Heck reaction used to introduce the sulfonamide side chain of naratriptan.
Scheme 16: Synthesis of the oxazolinone appendage of zolmitriptan.
Scheme 17: Grandberg indole synthesis used in the preparation of rizatriptan.
Scheme 18: Improved synthesis of rizatriptan.
Scheme 19: Larock-type synthesis of rizatriptan.
Scheme 20: Synthesis of eletriptan.
Scheme 21: Heck coupling for the indole system in eletriptan.
Scheme 22: Attempted Fischer indole synthesis of elatriptan.
Scheme 23: Successful Fischer indole synthesis for eletriptan.
Scheme 24: Mechanistic rationale for the Bischler–Möhlau reaction.
Scheme 25: Bischler-type indole synthesis used in the fluvastatin sodium synthesis.
Scheme 26: Palladium-mediated synthesis of ondansetron.
Scheme 27: Fischer indole synthesis of ondansetron.
Scheme 28: Optimised Pictet–Spengler reaction towards tadalafil.
Figure 4: Structures of carvedilol 136 and propranolol 137.
Scheme 29: Synthesis of the carbazole core of carvedilol.
Scheme 30: Alternative syntheses of 4-hydroxy-9H-carbazole.
Scheme 31: Convergent synthesis of etodolac.
Scheme 32: Alternative synthesis of etodolac.
Figure 5: Structures of imidazole-containing drugs.
Scheme 33: Synthesis of functionalised imidazoles towards losartan.
Scheme 34: Direct synthesis of the chlorinated imidazole in losartan.
Scheme 35: Synthesis of trisubstituted imidazoles.
Scheme 36: Preparation of the imidazole ring in olmesartan.
Scheme 37: Synthesis of ondansetron.
Scheme 38: Alternative route to ondansetron and its analogues.
Scheme 39: Proton pump inhibitors and synthesis of esomeprazole.
Scheme 40: Synthesis of benzimidazole core pantoprazole.
Figure 6: Structure of rabeprazole 194.
Scheme 41: Synthesis of candesartan.
Scheme 42: Alternative access to the candesartan key intermediate 216.
Scheme 43: .Medicinal chemistry route to telmisartan.
Scheme 44: Improved synthesis of telmisartan.
Scheme 45: Synthesis of zolpidem.
Scheme 46: Copper-catalysed 3-component coupling towards zolpidem.
Figure 7: Structure of celecoxib.
Scheme 47: Preparation of celecoxib.
Scheme 48: Alternative synthesis of celecoxib.
Scheme 49: Regioselective access to celecoxib.
Scheme 50: Synthesis of pazopanib.
Scheme 51: Syntheses of anastrozole, rizatriptan and letrozole.
Scheme 52: Regioselective synthesis of anastrozole.
Scheme 53: Triazine-mediated triazole formation towards anastrozole.
Scheme 54: Alternative routes to 1,2,4-triazoles.
Scheme 55: Initial synthetic route to sitagliptin.
Figure 8: Binding of sitagliptin within DPP-IV.
Scheme 56: The process route to sitagliptin key intermediate 280.
Scheme 57: Synthesis of maraviroc.
Scheme 58: Synthesis of alprazolam.
Scheme 59: The use of N-nitrosoamidine derivatives in the preparation of fused benzodiazepines.
Figure 9: Structures of itraconazole, ravuconazole and voriconazole.
Scheme 60: Synthesis of itraconazole.
Scheme 61: Synthesis of rufinamide.
Scheme 62: Representative tetrazole formation in valsartan.
Figure 10: Structure of tetrazole containing olmesartan, candesartan and irbesartan.
Scheme 63: Early stage introduction of the tetrazole in losartan.
Scheme 64: Synthesis of cilostazol.
Figure 11: Structure of cefdinir.
Scheme 65: Semi-synthesis of cefdinir.
Scheme 66: Thiazole syntheses towards ritonavir.
Scheme 67: Synthesis towards pramipexole.
Scheme 68: Alternative route to pramipexole.
Scheme 69: Synthesis of famotidine.
Scheme 70: Efficient synthesis of the hyperuricemic febuxostat.
Scheme 71: Synthesis of ziprasidone.
Figure 12: Structure of mometasone.
Scheme 72: Industrial access to 2-furoic acid present in mometasone.
Scheme 73: Synthesis of ranitidine from furfuryl alcohol.
Scheme 74: Synthesis of nitrofurantoin.
Scheme 75: Synthesis of benzofuran.
Scheme 76: Synthesis of amiodarone.
Scheme 77: Synthesis of raloxifene.
Scheme 78: Alternative access to the benzo[b]thiophene core of raloxifene.
Scheme 79: Gewald reaction in the synthesis of olanzapine.
Scheme 80: Alternative synthesis of olanzapine.
Figure 13: Access to simple thiophene-containing drugs.
Scheme 81: Synthesis of clopidogrel.
Scheme 82: Pictet–Spengler reaction in the preparation of tetrahydrothieno[3,2-c]pyridine (422).
Scheme 83: Alternative synthesis of key intermediate 422.
Figure 14: Co-crystal structures of timolol (left) and carazolol (right) in the β-adrenergic receptor.
Scheme 84: Synthesis of timolol.
Scheme 85: Synthesis of tizanidine 440.
Scheme 86: Synthesis of leflunomide.
Scheme 87: Synthesis of sulfamethoxazole.
Scheme 88: Synthesis of risperidone.
Figure 15: Relative abundance of selected transformations.
Figure 16: The abundance of heterocycles within top 200 drugs (5-membered rings).
Beilstein J. Org. Chem. 2011, 7, 254–264, doi:10.3762/bjoc.7.34
Graphical Abstract
Figure 1: Synthesized compounds 1 and 2.
Scheme 1: Synthesis of 1 and 2.
Figure 2: Energy optimized geometry of 1 with H2PO4− (E = 92.14 kcal/mol, a = 2.45 Å, b = 1.94 Å, c = 2.34 Å, ...
Figure 3: Change in fluorescence emission of 1 (c = 5.78 × 10−5 M) in the presence of 2 equiv of tetrabutylam...
Figure 4: Change in emission spectra of 1 (c = 5.78 × 10−5 M) in presence of increasing amounts of H2PO4− in ...
Figure 5: Suggested modes of binding of the H2PO4− ion into the cleft of 1.
Figure 6: Plot of change in emission of 1 at 420 nm vs the ratio of guest to host concentration in CH3CN.
Figure 7: Fluorescence Job plot of 1 with H2PO4−.
Figure 8: Change in fluorescence emission of 2 (c = 3.93 × 10−5 M) in the presence of 1 equiv of tetrabutylam...
Figure 9: Stern–Volmer plots for 1 (c = 5.78 × 10−5 M) with H2PO4−, F−, Br− and I− at 420 nm (up to the addit...
Figure 10: Change in UV–vis spectra of 1 (c = 5.78 × 10−5 M) in presence of increasing amounts of H2PO4− in CH3...
Figure 11: Change in fluorescence emission of 1 (c = 5.78 × 10−5 M) in the presence of 2 equiv of tetrabutylam...
Figure 12: Stern–Volmer plots for 1 (c = 5.78 × 10−5 M) with H2PO4−, F−, Br− and I− at 420 nm (up to the addit...
Figure 13: Fluorescence decays (at λmax = 420 nm) of receptor 1 upon the addition of H2PO4− ion ([H] = 5.78 × ...
Figure 14: Fluorescence decays (at λmax = 420 nm) of receptor 1 upon the addition of I− ion ([H] = 5.78 × 10−5...
Figure 15: Partial 1H NMR (300 MHz, CDCl3 containing 4% CD3CN) spectra of (a) 1 (c = 1.38 × 10−3 M), (b) 1:1 a...
Beilstein J. Org. Chem. 2011, 7, 46–52, doi:10.3762/bjoc.7.8
Graphical Abstract
Figure 1: (a) Receptor 1. (b) ORTEP drawing of receptor 1. Thermal ellipsoids are drawn at the 30% probabilit...
Figure 2: The absorption spectra of receptor 1 (5 μM) in the absence or presence of a 50 equiv of F−, Cl−, Br−...
Figure 3: The fluorescence spectra of receptor 1 (5 μM) in the absence or presence of a 50 equiv of F−, Cl−, ...
Figure 4: Comparison of fluorescence emission of 1 (5 μM) in CH3CN after the addition of 50 equiv of tetrabut...
Figure 5: UV–vis absorption changes of 1 (5 μM) upon the addition of TBAF in CH3CN.
Figure 6: Fluorescence emission changes of 1 (5 μM) upon the addition of TBAF in CH3CN (excited at 340 nm).
Figure 7: The fit of the experimental data of fluorescence emission of 1 (5 μM) upon the addition of F− at 40...
Figure 8: Fluorescence emission changes of 1 (5 μM) upon the addition of F− and OH− (5 equiv) in CH3CN (excit...
Figure 9: Partial 1H NMR (400 MHz) spectra of receptor 1 in the presence of 0, 0.2, 0.6, 1.0, 1.4, 1.6, 2.0, ...
Figure 10: Anionic form a and b of receptor 1.
Beilstein J. Org. Chem. 2010, 6, 1174–1179, doi:10.3762/bjoc.6.134
Graphical Abstract
Scheme 1: Lipase-catalyzed acetylation of racemic benzylic secondary alcohol [(RS)-4] and its application.
Scheme 2: FeCl3-meditated synthesis of bis-imines.
Scheme 3: Preparation of racemic 3-(1-hydroxyethyl)phenyl ethyl(methyl)carbamate [(RS)-4]
Scheme 4: Proposed reaction mechanism of lipase-catalyzed acetylation of racemic alcohol 4.
Scheme 5: Complete synthesis of rivastigmine.
Beilstein J. Org. Chem. 2010, 6, 1070–1078, doi:10.3762/bjoc.6.122
Graphical Abstract
Scheme 1: Structure of the quarterthiophene derivative T1.
Scheme 2: Synthetic route to T1. Reagent and conditions: a) Boc anhydride, CH2Cl2, 6 h, 0 °C–rt, 97%; b) NBS,...
Figure 1: AFM height images of a film spin-coated from diluted gel solution of T1 in MCH (2 × 10−3 M) onto HO...
Figure 2: a) UV-vis spectra of T1 in chloroform (dashed line) and n-heptane (solid line); b) UV-vis spectra o...
Scheme 3: Proposed mode of self-assembly of T1.
Figure 3: UV-vis spectra of T1 (concentration 5 x 10−5 M) in cyclohexane (solid line) and 2.4% MeOH in cycloh...
Figure 4: AFM height images (A and B) of a film spin-coated from MCH solution (concentration 5 x 10−4 M) of a...
Figure 5: Variation of dose-normalized conductivity transients (Δσ/D) with time for T1.
Beilstein J. Org. Chem. 2010, 6, 973–977, doi:10.3762/bjoc.6.109
Graphical Abstract
Figure 1: Molecular structures of β-Ala-His-EO2-C14 (a) and Gly-Gly-His-EO2-C14 (b).
Figure 2: ATR spectra of β-Ala-His-EO2-C14 in xerogel and D2O hydrogel, respectively.
Figure 3: SAXS profile of concentrated gel of β-Ala-His-EO2-C14 at different temperatures (where S = 2π/q and...
Figure 4: SEM micrographs of β-Ala-His-EO2-C14 hydrogels after drying.
Figure 5: 2D/3D self assembling of β-Ala-His-EO2-C14.
Beilstein J. Org. Chem. 2010, 6, 859–868, doi:10.3762/bjoc.6.101
Graphical Abstract
Figure 1: Structure of amphiphiles 1–5.
Scheme 1: Synthetic procedure of the amphiphiles.
Figure 2: Variation of the Tgel with concentration of amphiphiles 1 and 2.
Figure 3: (a, b) FESEM images of the dried gels of 1 and 2, respectively at their MGC. (c, d) Two- and three-...
Figure 4: Luminescence spectra of 2 in water (λex = 330 nm) at various concentrations and room temperature.
Figure 5: FTIR spectra of (a) 1 and (b) 2 in CHCl3 solution (dashed line) and in D2O at the gel state (solid ...
Figure 6: 2D-NOESY spectra of 2 (2%, w/v) in DMSO-d6 with 70% water.
Figure 7: XRD diagram of the dried gel of 2.
Figure 8: Schematic representation of the possible arrangement of molecules during hydrogelation of 2.
Figure 9: MTT assay based percent NIH3T3 cell viability as a function of concentration of amphiphile 2.
Beilstein J. Org. Chem. 2010, 6, No. 62, doi:10.3762/bjoc.6.62
Graphical Abstract
Figure 1: Vicinal difluoride containing building blocks.
Scheme 1: Synthesis of meso-2,3-difluoro-1,4-butanediol.
Scheme 2: Monoprotection of 3, and activation of the remaining alcohol.
Scheme 3: Reaction of 12 leading to defluorinated products.
Figure 2: Molecular overlay of both conformers of 7.
Figure 3: Crystal packing of 7 viewed along the b axis. Short contacts (see text) are shown in light blue.
Figure 4: Crystal structure of 3.
Figure 5: Crystal packing of 3 viewed along the c axis. H-bonds are shown in light blue.
Beilstein J. Org. Chem. 2010, 6, No. 38, doi:10.3762/bjoc.6.38
Graphical Abstract
Figure 1: Conformational effects associated with C–F bonds.
Figure 2: HIV protease inhibitor Indinavir (17) and fluorinated analogues 18 and 19. In analogue 18 the gauche...
Figure 3: Cholesteryl ester transfer protein inhibitors 20 and 21. In the fluorinated analogue 21, nO→σ*CF hy...
Figure 4: HIV reverse transcriptase inhibitor 22 and acid-stable fluorinated analogues 23–25. The F–C–C–O gau...
Figure 5: Dihydroquinidine (26) and fluorinated analogues 27 and 28. Newman projections along the C9–C8 bonds...
Figure 6: The neurotransmitter GABA (29) and fluorinated analogues (R)-30 and (S)-30. Newman projections of (R...
Figure 7: The insect pheromone 31 and fluorinated analogues (S)-32 and (R)-32. The proposed bioactive conform...
Figure 8: Capsaicin (33) and fluorinated analogues (R)-34 and (S)-34.
Figure 9: Asymmetric epoxidation reaction catalysed by pyrrolidine 35. Inset: the geometry of the activated i...
Figure 10: The asymmetric transannular aldol reaction catalysed by trans-4-fluoroproline (41), and its applica...
Figure 11: The asymmetric Stetter reaction catalysed by chiral NHC catalysts 49–52. The ring conformations of ...
Figure 12: A multi-vicinal fluoroalkane.
Figure 13: X-ray crystal structures of diastereoisomeric multi-vicinal fluoroalkanes 55 and 56. The different ...
Figure 14: Examples of fluorinated liquid crystal molecules. Arrows indicate the orientation of the molecular ...
Figure 15: Di-, tri- and tetra-fluoro liquid crystal molecules 60–62.
Figure 16: Collagen mimics of general formula (Pro-Yaa-Gly)10 where Yaa is either 4(R)-hydroxyproline (63) or ...
Figure 17: Enkephalin-related peptide 64 and the fluorinated analogue 65. The electron-withdrawing trifluorome...
Figure 18: The C–F bond influences the conformation of β-peptides. β-Heptapeptide 66 adopts a helical conforma...
Figure 19: The conformations of pseudopeptides 69 and 70 are influenced by the α-fluoroamide effect and the fl...
Beilstein J. Org. Chem. 2010, 6, No. 32, doi:10.3762/bjoc.6.32
Graphical Abstract
Figure 1: Biologically important amines and quaternary ammonium salts: histamine (1), dopamine (2) and acetyl...
Figure 2: Crown ether 18-crown-6.
Figure 3: Conformations of 18-crown-6 (4) in solvents of different polarity.
Figure 4: Binding topologies of the ammonium ion depending on the crown ring size.
Figure 5: A “pseudorotaxane” structure consisting of 24-crown-8 and a secondary ammonium ion (5); R = Ph.
Figure 6: Typical examples of azacrown ethers, cryptands and related aza macrocycles.
Figure 7: Binding of ammonium to azacrown ethers and cryptands [111-113].
Figure 8: A 19-crown-6-ether with decalino blocking groups (11) and a thiazole-dibenzo-18-crown-6-ether (12).
Figure 9: 1,3-Bis(6-oxopyridazin-1-yl)propane derivatives 13 and 14 by Campayo et al.
Figure 10: Fluorescent azacrown-PET-sensors based on coumarin.
Figure 11: Two different pyridino-cryptands (17 and 18) compared to a pyridino-crown (19); chiral ammonium ion...
Figure 12: Pyridino-18-crown-6 ligand (21), a similar acridino-18-crown-6 ligand (22) and a structurally relat...
Figure 13: Ciral pyridine-azacrown ether receptors 24.
Figure 14: Chiral 15-crown-5 receptors 26 and an analogue 18-crown-6 ligand 27 derived from amino alcohols.
Figure 15: C2-symmetric chiral 18-crown-6 amino alcohol derivatives 28 and related macrocycles.
Figure 16: Macrocycles with diamide-diester groups (30).
Figure 17: C2-symmetric chiral aza-18-crown-6 ethers (31) with phenethylamine residues.
Figure 18: Chiral C-pivot p-methoxy-phenoxy-lariat ethers.
Figure 19: Chiral lariat crown ether 34.
Figure 20: Sucrose-based chiral crown ether receptors 36.
Figure 21: Permethylated fructooligosaccharide 37 showing induced-fit chiral recognition.
Figure 22: Biphenanthryl-18-crown-6 derivative 38.
Figure 23: Chiral lariat crown ethers derived from binol by Fuji et al.
Figure 24: Chiral phenolic crown ether 41 with “aryl chiral barriers” and guest amines.
Figure 25: Chiral bis-crown receptor 43 with a meso-ternaphthalene backbone.
Figure 26: Chromogenic pH-dependent bis-crown chemosensor 44 for diamines.
Figure 27: Triamine guests for binding to receptor 44.
Figure 28: Chiral bis-crown phenolphthalein chemosensors 46.
Figure 29: Crown ether amino acid 47.
Figure 30: Luminescent receptor 48 for bis-alkylammonium guests.
Figure 31: Luminescent CEAA (49a), a bis-CEAA receptor for amino acids (49b) and the structure of lysine bindi...
Figure 32: Luminescent CEAA tripeptide for binding small peptides.
Figure 33: Bis crown ether 51a self assembles co-operatively with C60-ammonium ion 51b.
Figure 34: Triptycene-based macrotricyclic dibenzo-[24]-crown-8 ether host 52 and guests.
Figure 35: Copper imido diacetic acid azacrown receptor 53a and the suggested His-Lys binding motif; a copper ...
Figure 36: Urea (54) and thiourea (55) benzo crown receptor for transport and extraction of amino acids.
Figure 37: Crown pyryliums ion receptors 56 for amino acids.
Figure 38: Ditopic sulfonamide bridged crown ether receptor 57.
Figure 39: Luminescent peptide receptor 58.
Figure 40: Luminescent receptor 59 for the detection of D-glucosamine hydrochloride in water/ethanol and lumin...
Figure 41: Guanidinium azacrown receptor 61 for simple amino acids and ditopic receptor 62 with crown ether an...
Figure 42: Chiral bicyclic guanidinium azacrown receptor 63 and similar receptor 64 for the enantioselective t...
Figure 43: Receptors for zwitterionic species based on luminescent CEAAs.
Figure 44: 1,10-Azacrown ethers with sugar podand arms and the anticancer agent busulfan.
Figure 45: Benzo-18-crown-6 modified β-cyclodextrin 69 and β-cyclodextrin functionalized with diaza-18-crown-6...
Figure 46: Receptors for colorimetric detection of primary and secondary ammonium ions.
Figure 47: Porphyrine-crown-receptors 72.
Figure 48: Porphyrin-crown ether conjugate 73 and fullerene-ammonium ion guest 74.
Figure 49: Calix[4]arene (75a), homooxocalix[4]arene (75b) and resorcin[4]arene (75c) compared (R = H, alkyl c...
Figure 50: Calix[4]arene and ammonium ion guest (R = H, alkyl, OAcyl etc.), possible binding sites; A: co-ordi...
Figure 51: Typical guests for studies with calixarenes and related molecules.
Figure 52: Lower rim modified p-tert-butylcalix[5]arenes 82.
Figure 53: The first example of a water soluble calixarene.
Figure 54: Sulfonated water soluble calix[n]arenes that bind ammonium ions.
Figure 55: Displacement assay for acetylcholine (3) with a sulfonato-calix[6]arene (84b).
Figure 56: Amino acid inclusion in p-sulfonatocalix[4]arene (84a).
Figure 57: Calixarene receptor family 86 with upper and lower rim functionalization.
Figure 58: Calix[6]arenes 87 with one carboxylic acid functionality.
Figure 59: Sulfonated calix[n]arenes with mono-substitution at the lower rim systematically studied on their r...
Figure 60: Cyclotetrachromotropylene host (91) and its binding to lysine (81c).
Figure 61: Calixarenes 92 and 93 with phosphonic acids groups.
Figure 62: Calix[4]arene tetraphosphonic acid (94a) and a double bridged analogue (94b).
Figure 63: Calix[4]arene tetraphosphonic acid ester (92c) for surface recognition experiments.
Figure 64: Calixarene receptors 95 with α-aminophosphonate groups.
Figure 65: A bridged homocalix[3]arene 95 and a distally bridged homocalix[4]crown 96.
Figure 66: Homocalix[3]arene ammonium ion receptor 97a and the Reichardt’s dye (97b) for colorimetric assays.
Figure 67: Chromogenic diazo-bridged calix[4]arene 98.
Figure 68: Calixarene receptor 99 by Huang et al.
Figure 69: Calixarenes 100 reported by Parisi et al.
Figure 70: Guest molecules for inclusion in calixarenes 100: DAP × 2 HCl (101a), APA (101b) and Lys-OMe × 2 HC...
Figure 71: Different N-linked peptido-calixarenes open and with glycol chain bridges.
Figure 72: (S)-1,1′-Bi-2-naphthol calixarene derivative 104 published by Kubo et al.
Figure 73: A chiral ammonium-ion receptor 105 based on the calix[4]arene skeleton.
Figure 74: R-/S-phenylalaninol functionalized calix[6]arenes 106a and 106b.
Figure 75: Capped homocalix[3]arene ammonium ion receptor 107.
Figure 76: Two C3 symmetric capped calix[6]arenes 108 and 109.
Figure 77: Phosphorous-containing rigidified calix[6]arene 110.
Figure 78: Calix[6]azacryptand 111.
Figure 79: Further substituted calix[6]azacryptands 112.
Figure 80: Resorcin[4]arene (75c) and the cavitands (113).
Figure 81: Tetrasulfonatomethylcalix[4]resorcinarene (114).
Figure 82: Resorcin[4]arenes (115a/b) and pyrogallo[4]arenes (115c, 116).
Figure 83: Displacement assay for acetylcholine (3) with tetracyanoresorcin[4]arene (117).
Figure 84: Tetramethoxy resorcinarene mono-crown-5 (118).
Figure 85: Components of a resorcinarene based displacement assay for ammonium ions.
Figure 86: Chiral basket resorcin[4]arenas 121.
Figure 87: Resorcinarenes with deeper cavitand structure (122).
Figure 88: Resorcinarene with partially open deeper cavitand structure (123).
Figure 89: Water-stabilized deep cavitands with partially structure (124, 125).
Figure 90: Charged cavitands 126 for tetralkylammonium ions.
Figure 91: Ditopic calix[4]arene receptor 127 capped with glycol chains.
Figure 92: A calix[5]arene dimer for diammonium salt recognition.
Figure 93: Calixarene parts 92c and 129 for the formation molecular capsules.
Figure 94: Encapsulation of a quaternary ammonium cation by two resorcin[4]arene molecules (NMe4+@[75c]2 × Cl−...
Figure 95: Encapsulation of a quaternary ammonium cation by six resorcin[4]arene molecules (NMe3D+@[130]6 × Cl−...
Figure 96: Structure and schematic of cucurbit[6]uril (CB[6], 131a).
Figure 97: Cyclohexanocucurbit[6]uril (CB′[6], 132) and the guest molecule spermine (133).
Figure 98: α,α,δ,δ-Tetramethylcucurbit[6]uril (134).
Figure 99: Structure of the cucurbituril-phthalhydrazide analogue 135.
Figure 100: Organic cavities for the displacement assay for amine differentiation.
Figure 101: Displacement assay methodology for diammonium- and related guests involving cucurbiturils and some ...
Figure 102: Nor-seco-Cucurbituril (±)-bis-ns-CB[6] (140) and guest molecules.
Figure 103: The cucurbit[6]uril based complexes 141 for chiral discrimination.
Figure 104: Cucurbit[7]uril (131c) and its ferrocene guests (142) opposed.
Figure 105: Cucurbit[7]uril (131c) guest inclusion and representative guests.
Figure 106: Cucurbit[7]uril (131c) binding to succinylcholine (145) and different bis-ammonium and bis-phosphon...
Figure 107: Paraquat-cucurbit[8]uril complex 149.
Figure 108: Gluconuril-based ammonium receptors 150.
Figure 109: Examples of clefts (151a), tweezers (151b, 151c, 151d) and clips (151e).
Figure 110: Kemp’s triacid (152a), on example of Rebek’s receptors (152b) and guests.
Figure 111: Amino acid receptor (154) by Rebek et al.
Figure 112: Hexagonal lattice designed hosts by Bell et al.
Figure 113: Bell’s amidinium receptor (156) and the amidinium ion (157).
Figure 114: Aromatic phosphonic acids.
Figure 115: Xylene phosphonates 159 and 160a/b for recognition of amines and amino alcohols.
Figure 116: Bisphosphonate recognition motif 161 for a colorimetric assay with alizarin complexone (163) for ca...
Figure 117: Bisphosphonate/phosphate clip 164 and bisphosphonate cleft 165.
Figure 118: N-Methylpyrazine 166a, N-methylnicotinamide iodide (166b) and NAD+ (166c).
Figure 119: Bisphosphate cavitands.
Figure 120: Bisphosphonate 167 of Schrader and Finocchiaro.
Figure 121: Tweezer 168 for noradrenaline (80b).
Figure 122: Different tripods and heparin (170).
Figure 123: Squaramide based receptors 172.
Figure 124: Cage like NH4+ receptor 173 of Kim et al.
Figure 125: Ammonium receptors 174 of Chin et al.
Figure 126: 2-Oxazolin-based ammonium receptors 175a–d and 176 by Ahn et al.
Figure 127: Racemic guest molecules 177.
Figure 128: Tripods based on a imidazole containing macrocycle (178) and the guest molecules employed in the st...
Figure 129: Ammonium ion receptor 180.
Figure 130: Tetraoxa[3.3.3.3]paracyclophanes 181 and a cyclophanic tetraester (182).
Figure 131: Peptidic bridged paraquat-cyclophane.
Figure 132: Shape-selective noradrenaline host.
Figure 133: Receptor 185 for binding of noradrenaline on surface layers from Schrader et al.
Figure 134: Tetraphosphonate receptor for binding of noradrenaline.
Figure 135: Tetraphosphonate 187 of Schrader and Finocchiaro.
Figure 136: Zinc-Porphyrin ammonium-ion receptors 188 and 189 of Mizutani et al.
Figure 137: Zinc porphyrin receptor 190.
Figure 138: Zinc porphyrin receptors 191 capable of amino acid binding.
Figure 139: Zinc-porphyrins with amino acid side chains for stereoinduction.
Figure 140: Bis-zinc-bis-porphyrin based on Tröger’s base 193.
Figure 141: BINAP-zinc-prophyrin derivative 194 and it’s guests.
Figure 142: Bisaryl-linked-zinc-porphyrin receptors.
Figure 143: Bis-zinc-porphyrin 199 for diamine recognition and guests.
Figure 144: Bis-zinc-porphyrin crown ether 201.
Figure 145: Bis-zinc-porphyrin 202 for stereodiscrimination (L = large substituent; S = small substituent).
Figure 146: Bis-zinc-porphyrin[3]rotaxane and its copper complex and guests.
Figure 147: Dien-bipyridyl ligand 206 for co-ordination of two metal atoms.
Figure 148: The ligand and corresponding tetradentate co-complex 207 serving as enantioselective receptor for a...
Figure 149: Bis(oxazoline)–copper(II) complex 208 for the recognition of amino acids in aqueous solution.
Figure 150: Zinc-salen-complexes 209 for the recognition tertiary amines.
Figure 151: Bis(oxazoline)–copper(II) 211 for the recognition of amino acids in aqueous solution.
Figure 152: Zn(II)-complex of a C2 terpyridine crown ether.
Figure 153: Displacement assay and receptor for aspartate over glutamate.
Figure 154: Chiral complex 214 for a colorimetric displacement assay for amino acids.
Figure 155: Metal complex receptor 215 with tripeptide side arms.
Figure 156: A sandwich complex 216 and its displaceable dye 217.
Figure 157: Lanthanide complexes 218–220 for amino acid recognition.
Figure 158: Nonactin (221), valinomycin (222) and vancomycin (223).
Figure 159: Monesin (224a) and a chiral analogue for enantiodiscrimination of ammonium guests (224b).
Figure 160: Chiral podands (226) compared to pentaglyme-dimethylether (225) and 18-crown-6 (4).
Figure 161: Lasalocid A (228).
Figure 162: Lasalocid derivatives (230) of Sessler et al.
Figure 163: The Coporphyrin I tetraanion (231).
Figure 164: Linear and cyclic peptides for ammonium ion recognition.
Figure 165: Cyclic and bicyclic depsipeptides for ammonium ion recognition.
Figure 166: α-Cyclodextrin (136a) and novocaine (236).
Figure 167: Helical diol receptor 237 by Reetz and Sostmann.
Figure 168: Ammonium binding spherand by Cram et al. (238a) and the cyclic[6]metaphenylacetylene 238b in compar...
Figure 169: Receptor for peptide backbone and ammonium binding (239).
Figure 170: Anion sensor principle with 3-hydroxy-2-naphthanilide of Jiang et al.
Figure 171: 7-bromo-3-hydroxy-N-(2-hydroxyphenyl)naphthalene 2-carboxamide (241) and its amine binding.
Figure 172: Naturally occurring catechins with affinity to quaternary ammonium ions.
Figure 173: Spiropyran (244) and merocyanine form (244a) of the amino acid receptors of Fuji et al.
Figure 174: Coumarin aldehyde (245) and its iminium species with amino acid bound (245a) by Glass et al.
Figure 175: Coumarin aldehyde appended with boronic acid.
Figure 176: Quinolone aldehyde dimers by Glass et al.
Figure 177: Chromogenic ammonium ion receptors with trifluoroacetophenone recognition motifs.
Figure 178: Chromogenic ammonium ion receptor with trifluoroacetophenone recognition motif bound on different m...
Beilstein J. Org. Chem. 2009, 5, No. 51, doi:10.3762/bjoc.5.51
Graphical Abstract
Scheme 1: 1-[4-(dodecyloxy)phenyl]-3-methyl-1H-imidazol-3-ium mesogenic salts.
Scheme 2: Synthesis of the imidazole A. Reaction conditions: (i) aryl iodide (1.37 mmol), imidazole (1.69 mmo...
Scheme 3: Synthesis of methyl imidazolium 1a. Reaction conditions: (i) MeI in sealed tube, 54 h at RT.
Figure 1: ORTEP view of compound 1a with partial labelling. The closest molecules are represented (with lower...
Figure 2: Packing diagram of compound 1a in projection in the (b,c) lattice plane. Large spheres represent th...
Scheme 4: Anion metathesis in water/CH2Cl2 as solvent.
Figure 3: Spectra of absorption (red line) and emission (blue line) of 1a.
Figure 4: TGA measurements of the compounds 1a–e (rate 10 °C·min−1, in air).
Figure 5: Phase transition temperatures of compounds 1a–e.
Figure 6: Powder X-ray diffraction pattern of compound 1a in the liquid crystal state (T = 120 °C).
Figure 7: The melting process involves the ruffling of the ionic sublayer. In the smectic phase, the ruffling...
Figure 8: Comparison of the molecular area S and of the ionic sublayer thickness dc (including mesogenic segm...
Figure 9: Variation with the counter-ion of the molecular area S and of the ionic sublayer thickness dc (incl...
Figure 10: Cyclic voltammogram of 1a in CH3CN (0.1 M NBu4PF6): (i), (ii) cathodic and anodic range of the volt...
Beilstein J. Org. Chem. 2008, 4, No. 52, doi:10.3762/bjoc.4.52
Graphical Abstract
Figure 1: Structures of compounds 1 and 2.
Scheme 1: Syntheses of receptors 1 and 2.
Figure 2: UV-vis spectra of 1 (c = 5.05 × 10−5 M) in different solvents.
Figure 3: UV-vis spectra of 2 (c = 5.05 × 10−5 M) in different solvents.
Figure 4: UV spectra of the complex of 1 with citric acid (c = 1.67 × 10−5 M) and its change of absorbance on...
Figure 5: UV spectra of the complex of 1 with D-(−)-tartaric acid (c = 1.67 × 10−5 M) and its change of absor...
Figure 6: UV spectra of the complex of 2 with citric acid (c = 1.67 × 10−5 M) and its change of absorbance on...
Figure 7: UV spectra of the complex of 2 with D-(−)-tartaric acid (c = 1.67 × 10−5 M) and its change of absor...
Figure 8: Fluorescence change of 1 in CHCl3 in the presence of carboxylic acids (λex = 290 nm).
Figure 9: Plot of the ratio of excimer to monomer emission vs concentration of the complex of 1 with citric a...
Figure 10: Fluorescence change of 1 in CHCl3 (c = 1.67 × 10−5 M) upon addition of citric acid dissolved in CHCl...
Figure 11: Fluorescence change of 1 in CHCl3 (c = 1.67 × 10−5 M) upon addition of D-(−)-tartaric acid dissolve...
Figure 12: Fluorescence change of 2 in CHCl3 in the presence of carboxylic acids (λex = 290 nm).
Figure 13: Fluorescence change of 2 in CHCl3 (c = 1.67 × 10−5 M) upon addition citric acid dissolved in CHCl3 ...
Figure 14: 1H NMR (in CDCl3) spectra of receptor 1 (c = 3.57 × 10−3 M; bottom) and the 1:1 complex with citric...
Figure 15: AM1 optimized geometries of the complexes of 1 with (a) citric acid, hydrogen bond distances: a = 2...
Figure 16: AM1 optimized geometry of the complex of 2 with citric acid, hydrogen bond distances: a = 2.12 Å, b...
Beilstein J. Org. Chem. 2007, 3, No. 24, doi:10.1186/1860-5397-3-24
Graphical Abstract
Scheme 1: Microwave promoted ene reaction of ethyl trifluoropyruvate with α-methyl styrene.
Scheme 2: Thiourea catalysed ene reaction.
Scheme 3: Asymmetric carbonyl ene reaction mediated by chiral thiourea.
Scheme 4: Reaction between ethyl trifluoropyruvate and various alkenes.
Beilstein J. Org. Chem. 2006, 2, No. 24, doi:10.1186/1860-5397-2-24
Graphical Abstract
Figure 1: Tetramic acid antibiotics from natural sources.
Scheme 1: Synthesis of tetronolactonyl aldehydes from L-ascorbic acid
Scheme 2: Synthesis of tetronolactonyl dienyl esters from etronolactonyl aldehydes
Figure 2: H-bonding in tetronolactonyl dienyl esters.
Scheme 3: Synthesis of 5-hydroxy lactams from dienyl tetronic esters
Scheme 4: Synthesis of dienyl tetramic acid from 5- hydroxy lactams
Beilstein J. Org. Chem. 2006, 2, No. 9, doi:10.1186/1860-5397-2-9
Graphical Abstract
Scheme 1: The furan-nitroacylate approach to poly hydroxylated ACHC derivatives
Scheme 2: Reagents: i. Furan (see box); ii. Zn, HCl., EtOH then Boc2O, Et3N, 2b 89%, 3b 77%; iii. KHMDS, THF,...
Figure 1: Selected NOESY Correlations for 6–9
Scheme 3: Reagents: i. mCPBA, CH2Cl2 11 : 12 (9 : 1) 77%, 15 82%; ii. Ac2O, Py then mCPBA, CH2Cl2 (13 only) 6...
Figure 2: Selected NOESY Correlations for 14–16 (R = Boc)
Scheme 4: Reagents: i. OsO4, Me3NO.H2O, acetone 18 78% from 4 ii. TBSCl, imidazole, CH2Cl2, 17 66% from 2b; i...
Figure 3: Selected NOESY correlations for 24 – 26
Scheme 5: Reagents: i. HClO4, H2O/acetone; v. Ac2O, pyridine; iii. H2, Pd/C, 24 71%, 25 67%, 26 71%